Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Jul 15.

Published in final edited form as: Clin Cancer Res. 2010 May 12;16(14):3786–3794. doi: 10.1158/1078-0432.CCR-10-0547

Table 4.

Treatment-related ≥grade 2 toxicities on the twice-daily vorinostat arm

	DL1 500 mg twice daily × 3		DL2 600 mg twice daily × 3		DL3 800 mg twice daily × 3
	n = 3 (G₂/G₃/G₄)		n = 6 (G₂/G₃/G₄)		n = 3 (G₂/G₃/G₄)
	1st cycle	Any cycle	1st cycle	Any cycle	1st cycle	Any cycle
Anemia	0/0/0	0/0/0	1/0/0	1/1/0	0/0/0	0/2/0
Neutropenia	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0	2/0/0
Thrombocytopenia	0/0/0	0/0/0	0/1/0	0/0/1	3/0/0	2/1/0
Nausea	1/0/0	2/0/0	3/0/0	3/0/0	0/0/0	0/0/0
Vomiting	1/0/0	1/0/0	1/0/0	1/0/0	0/0/0	0/0/0
Diarrhea	1/0/0	1/0/0	1/0/0	1/0/0	1/0/0	0/1/0
Anorexia	0/0/0	2/0/0	2/0/0	2/0/0	1/0/0	2/0/0
Fatigue	2/0/0	3/0/0	3/0/0	3/1/0	2/1^*/0	1/2/0
Mucositis	0/0/0	1/0/0	0/0/0	0/0/0	1/1^/0^	2/1/1
Chelitis	0/0/0	0/0/0	0/0/0	0/0/0	1/0/0	2/0/0
Esophagitis	0/0/0	1/0/0	0/0/0	0/0/0	1/0/0	1/0/0
Dehydration	0/0/0	0/0/0	0/0/0	2/0/0	2/0/0	2/0/0
Fever	0/0/0	1/0/0	0/0/0	0/0/1	0/0/0	0/0/0
Headache	0/0/0	0/0/0	0/0/0	0/1/0	0/0/0	0/0/0
VTE	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0	0/0/1
ATE	0/0/0	0/0/0	0/0/0	0/0/0	0/0/0	0/0/1

^*

Two patients experienced a DLT at DL3.